AMRX

As of 2026-09-10, AMRX scores 48out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. AMRX trades at $16.87, within its fair-value band.

AMRX scores 48 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 48. Its strongest factor is sentiment at 58 (solid), where analyst and positioning signals are improving, followed by momentum at 57. The weakest is quality at 44, where earnings-quality metrics lag. Among Healthcare stocks it ranks in roughly the top 42% of the Healthcare names the model scores.

On valuation, AMRX is priced near the floor of its own recent range — the cheap end on the model's valuation read. The five factors sit close together, so the composite reflects a balanced profile rather than one dominant driver. The blended composite before the macro overlay was 50. Same-sector names the model rates nearby include HALO, THC, TGTX.

This is a descriptive factor read on AMRX, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where AMRX sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for AMRX runs $16.44–$23.78. Current price $16.87 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-10.